What counseling points should be provided to a patient starting tirzepatide (Mounjaro) therapy?

Tirzepatide Counseling Points

When initiating tirzepatide, counsel patients primarily on gastrointestinal side effects (nausea, vomiting, diarrhea occurring in 25% of patients), proper injection technique to avoid dosing errors, and the need to report severe abdominal pain immediately for potential pancreatitis. 1

Critical Safety Warnings

Thyroid C-Cell Tumor Risk

• Report immediately: Any neck lump, persistent hoarseness, difficulty swallowing, or shortness of breath
• Contraindicated in patients with personal or family history of medullary thyroid cancer or Multiple Endocrine Neoplasia syndrome type 2 1

Pancreatitis Recognition

• Stop medication and seek care immediately if experiencing severe abdominal pain that may radiate to the back, with or without vomiting
• This is a medical emergency requiring prompt evaluation 1

Common Side Effects and Management Strategies

Gastrointestinal Effects (Most Common)

The most frequent adverse events are gastrointestinal, typically mild-to-moderate and occurring primarily during the first 20 weeks of dose escalation 1, 2:

Practical management strategies 3:

• Eat smaller, more frequent meals
• Stop eating when feeling full
• Eat slowly and chew thoroughly
• Drink plenty of water throughout the day
• Increase dietary fiber gradually
• Avoid high-fat, greasy, or spicy foods
• Limit alcohol and carbonated beverages
• Many patients develop tolerance over time

Injection Site Issues

Critical counseling on dosing errors: Incorrect dose administration was the most reported adverse event in real-world data, increasing 8-fold from 2022 to 2024 with strong risk signals (ROR 22.15-23.43) 4. This represents a significant patient safety concern requiring:

• Detailed demonstration of proper injection technique
• Clear written instructions
• Verification of patient understanding before first home dose
• Injection site reactions (pain, redness) occur in 3.2% of patients 1

Drug Interactions and Contraindications

Medication Adjustments Required

Insulin and sulfonylureas: Reduce doses when starting tirzepatide to prevent hypoglycemia 1

Oral contraceptives:

• Switch to non-oral contraceptive method OR add barrier method for 4 weeks after initiation and 4 weeks after each dose escalation
• Tirzepatide delays gastric emptying, potentially affecting oral medication absorption 1

Never combine with GLP-1 receptor agonists - tirzepatide should not be given with other GLP-1 agonists but can be combined with SGLT-2 inhibitors 5

Medications Requiring Monitoring

• Warfarin and other narrow therapeutic index drugs require closer monitoring due to delayed gastric emptying 1

Cardiovascular and Kidney Considerations

For patients at higher cardiovascular/kidney risk: Tirzepatide should generally not replace medications with proven cardiovascular and kidney benefits. If switching from a GLP-1 receptor agonist to tirzepatide, ensure SGLT-2 inhibitor is initiated or continued 5

The evidence for cardiovascular and kidney benefits with tirzepatide remains uncertain (low to very low certainty), while GLP-1 receptor agonists have high certainty evidence for these outcomes 5

Dehydration and Kidney Function

Prevent dehydration: Due to gastrointestinal side effects (nausea, vomiting, diarrhea), patients must maintain adequate fluid intake to prevent acute kidney injury 1

Report immediately: Signs of kidney problems including decreased urination, swelling in legs/feet, unusual fatigue, or confusion

Gallbladder Disease Risk

Tirzepatide increases risk of acute gallbladder disease (cholelithiasis, biliary colic) occurring in 0.6% of patients 1. All GLP-1 receptor agonists share this risk 3.

Report: Right upper abdominal pain, especially after meals, nausea with abdominal pain, or yellowing of skin/eyes

Vision Changes

Contact healthcare provider if experiencing any vision changes during treatment, as diabetic retinopathy complications have been reported 1

Surgical Considerations

Critical pre-operative counseling: Tirzepatide causes delayed gastric emptying, increasing risk of pulmonary aspiration during general anesthesia or deep sedation 1. Patients must inform their surgeon and anesthesiologist about tirzepatide use before any planned procedures.

Expected Benefits to Emphasize

Weight Loss

• Mean weight loss of 8.63 kg (moderate certainty evidence) 5
• At 72 weeks: 15% loss with 5mg, 19.5% with 10mg, 20.9% with 15mg doses 6
• Patients with higher baseline weight experience larger absolute reductions 5
• 50-57% of patients achieve ≥20% weight loss with 10-15mg doses 6

Glycemic Control

• 85-91% of patients achieve HbA1c <7% depending on dose 1
• Significant improvements in fasting glucose 1

Additional Benefits

Patients in exit interviews reported 7:

• Decreased appetite (79%)
• Increased energy (79%)
• Improvements in quality of life and daily activities
• 96% of patients would recommend tirzepatide to others

Storage and Administration

• Store in refrigerator at 2°C to 8°C (36°F to 46°F)
• Can be stored unrefrigerated up to 30°C (86°F) for maximum 21 days if needed
• Never freeze; discard if frozen
• Keep in original carton to protect from light 1
• Subcutaneous injection once weekly 1

Common Pitfall to Avoid

The most critical error in real-world use is incorrect dosing 4. Ensure patients understand the dose escalation schedule and can correctly identify their prescribed dose on the pen device before leaving the clinic.